Serina Therapeutics President and CEO Randall Moreadith, MD, PhD to present at annual BIO Investor Forum in San Francisco
For Immediate Release October 9, 2012

Huntsville, AL - Serina Therapeutics, Inc., an early stage polymer drug delivery company, announced today that Dr. Randall Moreadith, President and CEO will present the company's programs in a special session for Discovery Companies at the annual BIO Investor Forum in San Francisco on October 10, 2012. The BIO Investor Forum is one of the premier events that brings together hundreds of companies and investors to share progress and ideas on promising technology in the life sciences. This year over 250 companies from all over the world will convene in San Francisco on October 9-10, 2012.

"It is a privilege to be chosen as one of the promising discovery stage companies to present at this year's event in San Francisco," stated Dr. Moreadith. "We have some compelling technology and two lead programs that will enter the clinic in the next two years, so it is time we got in front of other companies and investors to tell them our story."

Serina Therapeutics, Inc. is developing novel approaches to the treatment of Parkinson’s disease and cancer.

About Serina

Serina Therapeutics is a privately held pharmaceutical company that develops novel polymer therapeutics based on its proprietary polyoxazoline (POZ) technology platforms. The founders and managers of Serina were formerly the key principals of Shearwater Polymers, a company that enabled nine approved polyethylene glycol (PEG) products for various pharmaceutical partners. Besides developing its own pipeline of pharmaceutical products, Serina is also partnering its technology with pharmaceutical companies to develop high value products addressing unmet clinical needs.

For more information on Serina Therapeutics, please visit http://www.serinatherapeutics.com